IL6 and coronary artery disorder: The table below summarizes the most significant studies from the last five years (2019–2024), both supporting and challenging the relevance of ET-1, IL-6, IL-8, and sVCAM-1 in CAD diagnosis and cardiovascular risk (Table 2).